VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 514 filers reported holding VANECK VECTORS ETF TR in Q1 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,050,612 | -13.1% | 1,116,708 | -2.8% | 0.03% | -8.8% |
Q2 2023 | $34,586,062 | -36.3% | 1,148,657 | -31.5% | 0.03% | -38.2% |
Q1 2023 | $54,257,453 | -9.2% | 1,677,201 | -19.6% | 0.06% | -14.1% |
Q4 2022 | $59,786,279 | +103.4% | 2,086,053 | +71.1% | 0.06% | +93.9% |
Q3 2022 | $29,399,000 | -72.8% | 1,218,927 | -69.2% | 0.03% | -70.8% |
Q2 2022 | $108,189,000 | +37.1% | 3,951,333 | +92.0% | 0.11% | +66.2% |
Q1 2022 | $78,929,000 | -76.0% | 2,058,132 | -79.9% | 0.07% | -60.9% |
Q4 2021 | $328,340,000 | +21.4% | 10,251,027 | +11.7% | 0.17% | +17.6% |
Q3 2021 | $270,561,000 | -26.0% | 9,180,928 | -14.7% | 0.15% | -23.7% |
Q2 2021 | $365,847,000 | +37.6% | 10,766,543 | +31.6% | 0.19% | +41.6% |
Q1 2021 | $265,919,000 | -52.7% | 8,182,129 | -47.6% | 0.14% | -50.4% |
Q4 2020 | $562,622,000 | +32.3% | 15,619,714 | +43.9% | 0.28% | +6.2% |
Q3 2020 | $425,186,000 | -40.9% | 10,857,634 | -44.6% | 0.26% | -49.4% |
Q2 2020 | $719,082,000 | +52.6% | 19,604,194 | -4.2% | 0.51% | +26.3% |
Q1 2020 | $471,354,000 | +130.6% | 20,458,100 | +193.1% | 0.41% | +175.0% |
Q4 2019 | $204,377,000 | -26.7% | 6,980,096 | -33.2% | 0.15% | -37.3% |
Q3 2019 | $278,921,000 | +215.7% | 10,442,602 | +202.1% | 0.24% | +202.6% |
Q2 2019 | $88,348,000 | -27.3% | 3,456,501 | -36.2% | 0.08% | -29.7% |
Q1 2019 | $121,539,000 | -76.3% | 5,421,011 | -77.7% | 0.11% | -79.2% |
Q4 2018 | $513,645,000 | +325.4% | 24,354,881 | +273.6% | 0.53% | +389.9% |
Q3 2018 | $120,732,000 | +0.6% | 6,518,991 | +21.2% | 0.11% | -7.6% |
Q2 2018 | $120,021,000 | +26.3% | 5,379,710 | +24.4% | 0.12% | +32.6% |
Q1 2018 | $95,025,000 | +27.4% | 4,323,216 | +34.7% | 0.09% | +32.8% |
Q4 2017 | $74,568,000 | +14.9% | 3,208,596 | +13.6% | 0.07% | +6.3% |
Q3 2017 | $64,870,000 | -72.6% | 2,825,369 | -73.7% | 0.06% | -72.7% |
Q2 2017 | $236,975,000 | -68.9% | 10,732,538 | -67.8% | 0.23% | -66.4% |
Q1 2017 | $761,099,000 | +9.0% | 33,366,934 | -0.0% | 0.69% | -1.2% |
Q4 2016 | $698,187,000 | -49.5% | 33,374,163 | -36.1% | 0.70% | -46.9% |
Q3 2016 | $1,381,453,000 | +71.9% | 52,268,394 | +80.3% | 1.31% | +47.0% |
Q2 2016 | $803,485,000 | – | 28,996,233 | – | 0.89% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Memorial Sloan Kettering Cancer Center | 738,500 | $20,220,000 | 66.82% |
Baymount Management LP | 145,000 | $3,970,000 | 28.08% |
New Harbor Financial Group, LLC | 1,371,341 | $37,547,000 | 18.51% |
New Harbor Financial Group, LLC | 1,291,700 | $35,366,000 | 17.44% |
MKP Capital Management, L.L.C. | 1,500,000 | $41,070,000 | 13.74% |
Windmill Hill Asset Management Ltd | 844,600 | $23,125,000 | 11.94% |
Hollow Brook Wealth Management LLC | 768,567 | $21,043,000 | 11.57% |
Grand Central Investment Group | 261,915 | $7,171,000 | 10.33% |
Point72 Europe (London) LLP | 1,467,000 | $40,166,000 | 8.50% |
Slate Path Capital LP | 4,600,000 | $125,948,000 | 7.87% |